AGENUS INC

AGENUS Inc. pioneers immuno‑oncology with checkpoint antibodies, delivering curative therapies and solid Nasdaq growth—discover how they’re reshaping cancer treatment.

Check out how Agenus Inc. defied expectations in Q1, breaking its 200‑day MA and showing a positive EPS amid a -1211.76 P/E—insider confidence, analyst split, and institutional interest suggest a possible biotech turnaround.

Agenus Inc. continues to make significant strides in immuno-oncology, driven by its commitment to developing groundbreaking cancer treatments, despite facing financial challenges and a volatile market.

Agenus Inc. navigates financial turbulence in the biotech sector, but strategic collaborations and pipeline developments offer a glimmer of hope for the company’s future.

Agenus Inc, a biotech firm specializing in immuno-oncology, has experienced significant financial volatility, with its stock price fluctuating between $1.38 and $18.74 in the past year.

Agenus Inc. and Zydus Lifesciences form a $141 million strategic partnership to accelerate the development and commercialization of immuno-oncology therapies, marking a new era in the fight against cancer.

Agenus Inc. is a key player in the immuno-oncology sector, with a focus on delivering impactful cancer treatments through innovative checkpoint antibodies and synergistic agents.

Agenus Inc. reported a net loss of $1.03 per share in Q1 2025, but exceeded revenue expectations and made progress on strategic initiatives to improve its financial health and advance its immuno-oncology pipeline.

Agenus Inc. is navigating financial challenges through strategic moves, including a plan to raise capital, leadership appointments, and a focus on operational efficiency, positioning the company for long-term growth and stability.

Agenus Inc. reported a Q1 2025 loss of $26.4 million, but exceeded Wall Street expectations with revenue of $24.1 million, marking a positive development for the biotech company.